Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | AbbVie Inc | 1,074 |
| 2 | Bristol Myers Squibb Co | 461 |
| 3 | Pfizer Inc | 274 |
| 4 | Takeda Pharmaceutical Co Ltd | 263 |
| 5 | Purdue Pharma LP | 208 |
| 6 | Medtronic PLC | 203 |
| 7 | Novartis AG | 191 |
| 8 | Abbott Laboratories | 183 |
| 9 | Emory University | 148 |
| 10 | Biogen Inc | 143 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 10,800 |
| 2 | A61P | Therapeutic activity (drug indications) | 10,150 |
| 3 | C07D | Heterocyclic compounds | 3,569 |
| 4 | C07K | Peptides | 2,207 |
| 5 | Y02A | Climate change adaptation | 1,435 |
| 6 | C12N | Microorganisms, enzymes | 911 |
| 7 | G01N | Investigating / analysing materials | 808 |
| 8 | A61M | Devices for introducing media into the body | 689 |
| 9 | C07C | Acyclic and carbocyclic compounds | 445 |
| 10 | A61L | Sterilising / disinfecting materials | 415 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Method of reducing somnolence in patients treated with tizanidine | 2002 | Acorda Therapeutics Inc | 36 |
| TIZANIDINE SUCCINATE SALT FORMS AND METHODS OF MAKING AND USING THE SAME | 2008 | Johnson and Johnson | 17 |
| A METHOD FOR THE PREPARATION OF TIZANIDINE HYDROCHLORIDE | 2010 | 13 | |
| Novel use of tizanidine or its derivatives | 2007 | 11 | |
| Green new process for preparing tizanidine hydrochloride | 2011 | 10 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 11 |
| 2017 | 10 |
| 2018 | 18 |
| 2019 | 17 |
| 2020 | 12 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 12 |
| 2024 | 10 |
| 2025 | 3 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Janne T. Backman | University of Helsinki | 11 |
| 2 | Kenji Momo | University of Tsukuba | 6 |
| 3 | Pertti J. Neuvonen | University of Helsinki | 6 |
| 4 | Mitsuo Tanabe | Nagoya City University | 5 |
| 5 | Matthew D. Hall | National Institutes of Health | 5 |
| 6 | Marika T. Granfors | University of Helsinki | 5 |
| 7 | Cynthia V. Dills | Northwestern University | 3 |
| 8 | Kelli M. Wilson | National Center for Advancing Translational Sciences | 3 |
| 9 | L Groves | Athena Group (United States) | 3 |
| 10 | Agostino Palmeri | University of Fribourg | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review | 2004 | 374 | Parkinson's Disease Mechanisms and Treatments |
| Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis | 2009 | 321 | Mesenchymal stem cell research |
| Practice Parameter: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review) | 2010 | 303 | Neurological disorders and treatments |
| Treatments for spasticity and pain in multiple sclerosis: a systematic review | 2003 | 267 | Multiple Sclerosis Research Studies |
| Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2 | 2009 | 263 | Pharmacogenetics and Drug Metabolism |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of tizanidine?
Which pharmaceutical companies hold the most patents related to tizanidine?
What are some commercial brand names for tizanidine?
Who are the most prolific authors publishing research on tizanidine?
What are the main patent application areas for tizanidine-related inventions?